Insulet Corporation (NASDAQ:PODD) stock is trading higher on Wednesday after the company reported better-than-expected fourth-quarter earnings and 2026 guidance.
Fourth-quarter adjusted earnings reached $1.55 per share, beating the consensus of $1.45.
The automated insulin delivery technology maker reported sales of $783.8 million, up 31.2% year over year or 29% in constant currency (CC), beating the consensus of $768.69 million, exceeding the high end of the company’s guidance range of 25% to 28% in constant currency.
Total Omnipod revenue was $781.8 million, up 33.5%, or 31.3% in constant currency. Drug Delivery revenue totaled $2.0 million.
Gross margin of 72.5%, up 40 basis points over the prior year. Operating income of $146.3 million, or 18.7% of revenue, up 40 basis points over the prior year.
Adjusted operating income of $146.2 million, …